TY  - JOUR
AU  - Schmidt, Julie A
AU  - Fensom, Georgina K
AU  - Rinaldi, Sabina
AU  - Scalbert, Augustin
AU  - Appleby, Paul N
AU  - Achaintre, David
AU  - Gicquiau, Audrey
AU  - Gunter, Marc J
AU  - Ferrari, Pietro
AU  - Kaaks, Rudolf
AU  - Kühn, Tilman
AU  - Boeing, Heiner
AU  - Trichopoulou, Antonia
AU  - Karakatsani, Anna
AU  - Peppa, Eleni
AU  - Palli, Domenico
AU  - Sieri, Sabina
AU  - Tumino, Rosario
AU  - Bueno-de-Mesquita, Bas
AU  - Agudo, Antonio
AU  - Sánchez, Maria-Jose
AU  - Chirlaque, María-Dolores
AU  - Ardanaz, Eva
AU  - Larrañaga, Nerea
AU  - Perez-Cornago, Aurora
AU  - Assi, Nada
AU  - Riboli, Elio
AU  - Tsilidis, Konstantinos K
AU  - Key, Timothy J
AU  - Travis, Ruth C
TI  - Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case-control sets from EPIC.
JO  - International journal of cancer
VL  - 146
IS  - 3
SN  - 1097-0215
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2019-01372
SP  - 720-730
PY  - 2020
N1  - Int J Cancer. 2020 Feb 1;146(3):720-730
AB  - Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD ) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD  = 0.77, 95
LB  - PUB:(DE-HGF)16
C6  - pmid:30951192
DO  - DOI:10.1002/ijc.32314
UR  - https://inrepo02.dkfz.de/record/143810
ER  -